EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biopharmaceut...
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated baseline inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026 APJ agonist program, an exercise-mimetic approach to obesity, on track for IND submission by year-end 2026 EMERYVILLE,
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...
Detailed price information for Freeport-Mcmoran Inc (FCX-N) from The Globe and Mail including charting and trades.
Detailed price information for Evommune Inc (EVMN-N) from The Globe and Mail including charting and trades.
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapyPrimary...
BioAge's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, and partnerships with Novartis and Eli Lilly. See why BIOA stock is a buy.
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...
This is the newest page. Registered accounts read further back.